Stay updated on Combination Dato-DXd Clinical Trial
Sign up to get notified when there's something new on the Combination Dato-DXd Clinical Trial page.

Latest updates to the Combination Dato-DXd Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.5%
- Check9 days agoChange DetectedThe page has been updated to reflect an increase in the number of study locations from 239 to 240, and the revision version has been updated from v2.15.0 to v2.16.0.SummaryDifference0.5%
- Check46 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study information regarding the efficacy and safety of datopotamab deruxtecan in combination with pembrolizumab for advanced non-small cell lung cancer, and the addition of new identifiers and collaborators related to the study.SummaryDifference20%
- Check80 days agoChange DetectedThe page now indicates that the study has increased to 238 locations, with a specific mention of Cankaya, Turkey, as a new location. Additionally, the last update date has changed to March 2025, reflecting the most recent information.SummaryDifference0.5%
- Check143 days agoChange DetectedThe website has updated to version v2.14.0, adding a 'Contact: Principal Investigator' section and a new 'Type of intervention' feature, while removing the previous version's 'type of intervention' and reverting to an earlier revision.SummaryDifference11%
- Check165 days agoChange DetectedThe study has increased from 236 to 237 locations, with the latest revision updated to v2.13.3.SummaryDifference0.4%
Stay in the know with updates to Combination Dato-DXd Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combination Dato-DXd Clinical Trial page.